External validation of previously reported prognostic classifications for patients treated with second-line axitinib after immuno-oncology combination therapy for advanced renal cell carcinoma: JUOG retrospective study.
Yuji Kujiraoka, Takahiro Osawa, Yuto Matsushita, Takahiro Kojima et autres